Related Experiment Video
Updated: Jun 26, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
The truncated AXIN1 isoform promotes hepatocellular carcinoma metastasis through SRSF9-mediated exon 9 skipping
Qian-Qian Zhang1, Ying-Shuang Miao2, Jun-Yi Hu2
1State Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Genomic Medicine, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Abstract:
Axis inhibitor protein 1 (AXIN1) is a protein recognized for inhibiting tumor growth and is commonly involved in cancer development. In this study, we explored the potential molecular mechanisms that connect alternative splicing of AXIN1 to the metastasis of hepatocellular carcinoma (HCC). Transcriptome sequencing, RT‒PCR, qPCR and Western blotting were utilized to determine the expression levels of AXIN1 in human HCC tissues and HCC cells. The effects of the AXIN1 exon 9 alternative splice isoform and SRSF9 on the migration and invasion of HCC cells were assessed through wound healing and Transwell assays, respectively. The interaction between SRSF9 and AXIN1 was investigated using UV crosslink RNA immunoprecipitation, RNA pulldown, and RNA immunoprecipitation assays. Furthermore, the involvement of the AXIN1 isoform and SRSF9 in HCC metastasis was validated in a nude mouse model. AXIN1-L (exon 9 including) expression was downregulated, while AXIN1-S (exon 9 skipping) was upregulated in HCC. SRSF9 promotes the production of AXIN1-S by interacting with the sequence of exons 8 and 10 of AXIN1. AXIN1-S significantly promoted HCC cells migration and invasion by activating the Wnt pathway, while the opposite effects were observed for AXIN1-L. In vivo experiments demonstrated that AXIN1-L inhibited HCC metastasis, whereas SRSF9 promoted HCC metastasis in part by regulating the level of AXIN1-S. AXIN1, a tumor suppressor protein that targets the AXIN1/Wnt/β-catenin signaling axis, may be a promising prognostic factor and a valuable therapeutic target for HCC.
Insights
Alternative splicing of Axis inhibitor protein 1 (AXIN1) impacts hepatocellular carcinoma (HCC) metastasis. AXIN1-S promotes HCC metastasis by activating the Wnt pathway, while AXIN1-L inhibits it, offering potential therapeutic targets.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Research
Background:
- Axis inhibitor protein 1 (AXIN1) is a known tumor suppressor involved in cancer development.
- Alternative splicing of AXIN1 may play a role in hepatocellular carcinoma (HCC) progression.
- Understanding the molecular mechanisms linking AXIN1 splicing to HCC metastasis is crucial for therapeutic development.
Purpose of the Study:
- To investigate the molecular mechanisms connecting AXIN1 alternative splicing to HCC metastasis.
- To elucidate the role of the AXIN1 exon 9 splice isoform and SRSF9 in HCC cell migration and invasion.
- To evaluate AXIN1 isoforms and SRSF9 as potential prognostic and therapeutic targets for HCC.
Main Methods:
- Transcriptome sequencing, RT-PCR, qPCR, and Western blotting were used to analyze AXIN1 expression in HCC tissues and cells.
- Wound healing and Transwell assays assessed the impact of AXIN1 isoforms and SRSF9 on HCC cell migration and invasion.
- RNA immunoprecipitation, UV crosslinking, and RNA pulldown assays investigated the interaction between SRSF9 and AXIN1.
Main Results:
- AXIN1-L (exon 9 included) was downregulated, while AXIN1-S (exon 9 skipped) was upregulated in HCC.
- SRSF9 promotes AXIN1-S production by interacting with AXIN1 exons 8 and 10.
- AXIN1-S enhanced HCC cell migration and invasion via Wnt pathway activation, whereas AXIN1-L had opposing effects. In vivo studies confirmed AXIN1-L inhibited metastasis, and SRSF9 promoted it.
Conclusions:
- AXIN1 alternative splicing, specifically the balance between AXIN1-L and AXIN1-S, significantly influences HCC metastasis.
- SRSF9 acts as an oncogene in HCC by promoting the pro-metastatic AXIN1-S isoform.
- Targeting the AXIN1/Wnt/β-catenin signaling axis through modulation of AXIN1 isoforms presents a promising therapeutic strategy for HCC.
More Related Videos
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
The Ras Gene
Ras is a...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Abnormal Proliferation
Non-LTR Retrotransposons

